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Abstract: Context
Islet autoantibodies are markers of type 1 diabetes and an increase in number of
autoantibodies detected during the preclinical phase is predictive of progression to
overt disease.
Objective
To refine the impact of age in relation to islet antibody type on the progression from
single to multiple autoantibodies in relatives of people with type 1 diabetes.
Research design and methods
We examined 994 relatives with normal glucose tolerance and positive for a single
autoantibody, followed prospectively in the TrialNet Pathway to Prevention. Antibodies
to GAD (GADA), insulin (IAA), IA-2 (IA-2A), zinc transporter 8 (ZnT8A) and ICA were
tested every 6-12 months. The primary outcome was confirmed development of
multiple autoantibodies. Age was categorized as <8yr; 8-11yr; 12-17yr; ≥18yr and
optimal age breakpoints identified by recursive partitioning analysis.
Results
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
After median follow-up of 2 years, 141 relatives had developed ≥ 1 additional
autoantibodies. Five-year risk was inversely related to age, but the pattern differed by
antibody type: relatives with GADA showed a gradual decrease in risk over the four
age groups, while relatives with IAA showed a sharp decrease above the age of 8
years. Recursive partitioning analysis identified age breakpoints at 14 years in relatives
with GADA and at 4 years in relatives with IAA.
Conclusions
In relatives with IAA, spread of islet autoimmunity is largely limited to early childhood,
while immune responses initially directed at GAD can mature over a longer period of
time. These differences have important implications for monitoring these subjects and
for designing prevention trials.
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Impact of age and antibody type on progression from single to multiple autoantibodies in type 1 diabetes 
relatives (jc.2017-00569). 
 
Dear Editor, 
In response to the comments of reviewers, please find hereafter our comments: 
 
Reviewer #1:  
In addition to the 994 relatives positive for a single autoantibody (GADA, IA-2A or IAA) with normal oral 
glucose tolerance at baseline: 
 
State how many of the 151,458 relatives screened in TrialNet PTP between March 1st 2004 and March 
31st 2015 were: 
1) single autoantibody-positive with dysglycaemia at baseline; 
2) multiple autoantibody-positive with normoglycaemia and dysglycaemia, respectively. 
 
Response: We appreciate the reviewer’s request for clarification related to how this cohort compares to 
those who were not included. Of all subjects who were confirmed as positive for a single autoantibody, 994 
were identified as normoglycaemic (presented in this manuscript) and an additional 276 subjects had 
abnormal glucose tolerance. We have included these clarifications in the text of the paper (line 136-138).  
We have specifically not included information related to those subjects who were positive for multiple 
autoantibodies; that cohort is being described through another manuscript.  
 
State how many of the 994 relatives were at baseline ZnT8A positive and negative, respectively, and 
consider this status in the analysis and interpretation. 
Response: As reported in the methods section (lines 102-104), participants included in this study were 
those screened and confirmed positive for only one autoantibody (GADA, IAA or IA-2A) and were also 
additionally tested for islet cell antibodies (ICA) and ZnT8A . Therefore, all 994 relatives included in these 
analyses were ZnT8A-negative, since any subjects who tested positive for ZnT8A (or any other additional 
autoantibody) were classified as multiple antibody-positive. 
 
Clarify the primary outcome: "… confirmed development of multiple autoantibodies defined as detection 
on two (subsequent?) occasions …" 
Response: We again appreciate the request for clarification on this important point. Indeed, the primary 
endpoint for this paper is confirmed development of multiple autoantibodies, which we have defined as 
being identified as having two or more positive autoantibodies (GADA, IAA, IA-2A, ZnT8A, or ICA). This 
positivity is required to be confirmed on two consecutive evaluations that are done within one year of each 
other. The date the subject was identified as confirmed positive for multiple autoantibodies is the date of 
the first multiple antibody positive result that was subsequently confirmed. This has been clarified in the 
text (lines 120-121).  
 
 
Importantly, the authors should include HLA in their analysis. 
Point-by-Point Rebuttal
Response: Analyses of the associations between HLA, autoantibody type and risk of progression in this 
group of confirmed single antibody-positive relatives have already been published in Bingley PJ et al. 
Diabetologia 2016;59:542-549 (ref 16). We do not therefore feel it is appropriate to add it to the present 
report. We have however highlighted the previous analysis in the discussion (line 183-185). 
 
Reviewer #2:  
It would be helpful briefly to describe the technique of recursive partitioning analysis. 
 
Response: We thank the reviewer for this helpful suggestion, and have included some clarification on this 
in the statistical methods section (lines 128-130). Overall, recursive partitioning is a model-based and 
iterative approach that can be used to identify cutpoints of a marker that best differentiate prognosis 
based on the outcome of interest, here, risk of progression to multiple positive autoantibodies.  
In Figures 1 and 2 the decimal points on the y-axis are unnecessary. 
 
Response: We acknowledge that decimal points are not necessarily required in these time-to-event Kaplan-
Meier plots for the distributions of time to progression to multiple positive autoantibodies. However, their 
inclusion is not erroneous. Nonetheless, we modified the formatting of the y-axis for Figures 2a and 2b to 
make it more readable. 
 
Perhaps add a rider that we do not know if this information necessarily holds true for older people 
developing type 1 diabetes in their thirties or forties. 
Response: We acknowledge that many of these subjects included in our analysis are younger. However, the 
age range for subjects in these analyses is from 1 to 51 years old at positive autoantibody determination. In 
fact, 375 of these subjects were 30 years or older. While we did not conduct a subset analysis focusing on 
these older subjects, they are indeed well represented in this cohort. 
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Context. Islet autoantibodies are markers of type 1 diabetes and an increase in number of 47 
autoantibodies detected during the preclinical phase is predictive of progression to overt disease. 48 
Objective. To refine the impact of age in relation to islet antibody type on the progression from 49 
single to multiple autoantibodies in relatives of people with type 1 diabetes. 50 
Research design and methods. We examined 994 relatives with normal glucose tolerance and 51 
positive for a single autoantibody, followed prospectively in the TrialNet Pathway to Prevention. 52 
Antibodies to GAD (GADA), insulin (IAA), IA-2 (IA-2A), zinc transporter 8 (ZnT8A) and ICA were 53 
tested every 6-12 months. The primary outcome was confirmed development of multiple 54 
autoantibodies. Age was categorized as <8yr; 8-11yr; 12-17yr; ≥18yr and optimal age breakpoints 55 
identified by recursive partitioning analysis.   56 
Results. After median follow-up of 2 years, 141 relatives had developed ≥ 1 additional 57 
autoantibodies. Five-year risk was inversely related to age, but the pattern differed by antibody 58 
type: relatives with GADA showed a gradual decrease in risk over the four age groups, while 59 
relatives with IAA showed a sharp decrease above the age of 8 years. Recursive partitioning 60 
analysis identified age breakpoints at 14 years in relatives with GADA and at 4 years in relatives 61 
with IAA. 62 
Conclusions. In relatives with IAA, spread of islet autoimmunity is largely limited to early 63 
childhood, while immune responses initially directed at GAD can mature over a longer period of 64 
time. These differences have important implications for monitoring these subjects and for 65 
designing prevention trials.  66 
Introduction 67 
Islet autoimmunity leading to type 1 diabetes develops and progresses silently over many years 68 
before glucose intolerance and symptomatic hyperglycemia occur (1). Islet autoantibodies are the 69 
best validated markers of this ongoing pathogenetic process and are used to predict clinical 70 
disease (2) and stage its preclinical phase (3).  71 
Several prospective studies, including those following infants at genetic risk from birth, have 72 
shown that the antibody response against β-cells within pancreatic islets usually targets several 73 
autoantigens including insulin (IAA), glutamic acid decarboxylase (GADA), insulinoma-associated 74 
antigen 2/ICA512 (IA2A) and zinc transporter 8 (ZnT8A), in varying sequence. Maturation of this 75 
humoral immune response, as shown by increasing autoantibody number, titer and affinity, is 76 
associated with an increased risk of progression to the disease (4).  77 
Specifically, the number of autoantibodies detected seems crucial for the prediction of disease, 78 
with a relatively low risk associated with positivity for a single autoantibody, increasing to near 79 
certainty of developing type 1 diabetes following the appearance of multiple (i.e. two or more) 80 
autoantibodies (4-13). Therefore, seroconversion from single to multiple autoantibodies appears 81 
to be the hallmark of a ‘point of no return’ in the type 1 diabetes pathogenetic process, marking 82 
the transition from a state of predisposition to a preclinical stage of the disease (3). Associations 83 
have been described with younger age and HLA class II genotype (6, 10), but the determinants of 84 
this maturation remain largely unknown.  85 
Previous analyses in relatives followed prospectively in the TrialNet Pathway to Prevention (PTP) 86 
(formerly Natural History Study) (14,15) have indicated heterogeneity in the development and 87 
spreading of islet autoantibody responses, and have also shown that progression from single to 88 
multiple autoantibodies is not restricted to early childhood and high risk genotypes (16,17). In light 89 
of this evidence and the implications for design of targeted interventions to prevent or delay 90 
progression of islet autoimmunity, we have undertaken a more in-depth investigation into the 91 
transition from single to multiple autoantibodies, with specific regard to the impact of age in 92 
relation to antibody type. 93 
Methods 94 
Study population 95 
 96 
Non-diabetic first, second and third degree relatives of people with type 1 diabetes were recruited 97 
to the TrialNet PTP (ClinicalTrials.gov identifier: NCT00097292) as previously described (14). All 98 
study participants gave informed consent and the Ethics Committee responsible for each clinical 99 
site approved the study. Participants were included in this analysis if they had antibodies to the 100 
same single islet autoantigen (GADA, IAA or IA-2A) detected on at least two occasions, and 101 
antibody results were available from at least one subsequent study visit. All samples were 102 
screened for GADA, IAA and IA-2A, and if levels of any of these were above the threshold of 103 
positivity, samples were additionally tested for islet cell antibodies (ICA) and ZnT8A. Individuals 104 
with confirmed islet autoantibodies underwent baseline assessment including oral glucose 105 
tolerance testing and were followed every 6–12 months in accordance with the PTP study 106 
protocol, as previously reported (14). Relatives with the protective HLA DQB1*0602 allele were 107 
not included in this analysis. 108 
 109 
Assays  110 
 111 
GADA, IAA, IA-2A and ZnT8A were measured by radioimmunoassay in the TrialNet Core laboratory 112 
at the Barbara Davis Center for Childhood Diabetes (BDC), Denver, CO and ICA by indirect 113 
immunofluorescence at the University of Florida, Gainesville, FL, as previously described (18-20). 114 
 115 
Statistical analysis  116 
 117 
The primary outcome of the analysis was confirmed development of multiple autoantibodies 118 
defined as detection on two occasions of at least two of the five islet autoantibodies included in 119 
the testing strategy (GADA, IAA, IA-2A, ZnT8A and ICA); this confirmation is based on two 120 
consecutive autoantibody tests that are done within one year of each other. The time-to-event 121 
was calculated from the date of first detection of a single islet autoantibody to date of first 122 
detection of multiple autoantibodies. The risk of developing multiple autoantibodies was assessed 123 
by survival analysis using Kaplan–Meier curves. Cox proportional hazards regression models were 124 
used for multivariable analysis. Age groups were initially categorized using boundaries based on 125 
common definitions of infancy to pre-pubertal, adolescence and adulthood (<8yr; 8-11yr; 12-17yr; 126 
≥18yr); and then refined by recursive partitioning analysis used to identify optimal age breakpoints 127 
within each single autoantibody population (21-23). Recursive partitioning is a model-based 128 
method used to identify a cutpoint for a marker that best differentiates subjects in relation to an 129 
outcome of interest, such as risk of progression to multiple positive autoantibodies.   130 
 131 
Results 132 
 133 
Of 151,458 relatives screened in the TrialNet PTP between March 1st 2004 and March 31st 2015, 134 
994 were positive for a single autoantibody (GADA, IAA or IA-2A) with normal oral glucose 135 
tolerance at baseline and were therefore eligible for inclusion in the analysis, while an additional 136 
276 subjects had abnormal glucose tolerance. Of the 994 positive for a single autoantibody with 137 
normal glucose tolerance, 709 (71.3%) had GADA, 236 (23.7%) had IAA and 49 (4.9%) had IA-2A; 138 
59.6% were female.  139 
 140 
The median age of the participants was 17.6 years (interquartile range 9.8 - 36.2); 183 (18.4%) 141 
were aged less than 8 years, 157 (15.8%) between 8 and 11 years, 169 (17.0%) between 12 and 17 142 
years and 485 (48.8%) 18 years or more.  143 
 144 
After a median follow-up of 2.0 years (IQR 0.8-3.8), 141 relatives had developed ≥ 1 additional 145 
autoantibodies. Estimated cumulative risk within 5 years was 23% (95% CI 19-27) overall, and did 146 
not vary between autoantibody types (GADA 25% [CI 20-30]; IAA 19% [CI 11-27]; IA-2A 23% [CI 7-147 
38]; p=0.09).   148 
The overall risk of developing additional autoantibodies was inversely related to age (multivariable 149 
HR 0.96, 95% CI 0.94-0.99, p=0.005), but heterogeneity between autoantibody type was identified. 150 
Table 1 shows the risk of developing multiple autoantibodies within 5 years categorized by age.  151 
Relatives with GADA showed a gradual decrease in risk across the four age groups, while relatives 152 
with IAA showed a sharp decrease in risk above the age of 8 years. Analysis between age groups 153 
was not performed in relatives with IA-2A due to an insufficient number of subjects.  154 
The age distribution of the relatives who developed multiple autoantibodies also differed between 155 
those with GADA or IAA (Figure 1). Relatives below 8 years of age represented 71% of the IAA-156 
positive individuals who became multiple autoantibody-positive within 5 years, while the  age of 157 
GADA-positive individuals who progressed were more evenly distributed throughout childhood 158 
and adolescence. Of the relatives who developed one or more additional autoantibodies, 17/24 159 
(71%) with IAA vs 22/99 (22%) with GADA were aged <8 years (p=0.048).  160 
Recursive partitioning analysis confirmed differences in age-related risk between GADA-positive 161 
and IAA-positive groups and identified age breakpoints at 14 years in relatives with GADA alone 162 
and 4 years in those with IAA alone. The survival time from initial detection of a single islet 163 
autoantibody to first detection of multiple antibodies in subgroups categorized by these age 164 
breakpoints for GADA-positive relatives is shown in Figure 2A, and for IAA-positive relatives in 165 
Figure 2B. Among the GADA-positive relatives, 99 individuals developed additional autoantibodies 166 
within 5 years, of whom 59 were aged less than 14 years and 40 were aged ≥14 years (estimated 167 
cumulative risk 35.2% [95% CI] (27.9, 43.8) vs 17.7% [95% CI] (12.6, 24.6), respectively; logrank 168 
test p<0.001). Among IAA-positive relatives, 24 individuals developed additional autoantibodies 169 
within 5 years, of whom 12 were aged less than 4 years and 12 were aged ≥4 years (estimated 170 
cumulative risk 73.1% [95% CI] (48.5, 92.6) vs 11.4% [95% CI] (6.3, 20.4), respectively; logrank test, 171 
p<0.001).  172 
Discussion 173 
 174 
The main finding of this analysis is that the interaction between age and risk of progression from 175 
single to multiple autoantibodies differs according to whether the primary autoantigen is GAD or 176 
insulin. Specific age breakpoints were very different in those initially positive for IAA compared to 177 
those with GADA. This suggests that early interventions targeting single autoantibody-positive 178 
individuals at risk for type 1 diabetes may differ in their effectiveness at different ages, depending 179 
on whether they have GADA or IAA and provides some guidance as to what age groups to target.  180 
Previous analyses in relatives followed prospectively in the TrialNet PTP (14,15) found that, in 181 
those positive for a single autoantibody, the risk of progression to multiple antibodies was 22% 182 
within 5 years and to type 1 diabetes was 6% (16). As confirmed in the present analysis, overall 183 
risk of development of multiple autoantibodies was independent of antibody type, inversely 184 
related to age, and associated with high and intermediate risk HLA Class II genotypes and high 185 
GADA titers (16). In addition, progression appeared not to be influenced by initial  body mass 186 
index or other metabolic variables (24). More recently, recursive partitioning analysis 187 
demonstrated that age and GADA titer taken together were helpful in stratifying the overall risk of 188 
progression from single to multiple autoantibodies (17). 189 
These additional analyses  focus on evaluation of the time course of progression among single 190 
autoantibody-positive subjects, depending whether the first autoantibodies detected were GADA 191 
or IAA. These demonstrate marked differences between the initial IAA and GADA groups. Although 192 
risk was inversely related to age in both groups, the relationships were not the same; while risk in 193 
GADA-positive relatives decreased gradually up to age 18 years, in IAA-positive relatives risk was 194 
concentrated in younger children with high risk of progression up to age 8 years, and a sharp 195 
decline thereafter. This pattern was confirmed by recursive partitioning analysis which showed 196 
significant differences in risk and identified different age breakpoints for IAA (4 years) and for 197 
GADA (14 years). 198 
Based on these observations, spread of autoimmunity from insulin to other islet antigens seems 199 
largely limited to early childhood, while autoimmune responses initially directed against GAD can 200 
mature over a longer period of time, including the whole of adolescence. It will be interesting to 201 
see whether this pattern is confirmed in studies of cellular immune responses.  202 
These findings are relevant to the design of prevention trials targeting the early phases of type 1 203 
diabetes-associated autoimmunity. In individuals with IAA alone, intervention should be 204 
considered only below the age of 8 years, with the highest priority given to individuals below 4 205 
years of age; conversely, in individuals with GADA alone, intervention seems justified up to the age 206 
of 18 years, with the highest potential below 14 years. Although there is no sharp decline after age 207 
18, the overall risk of developing additional antibodies is relatively low in GADA-positive adults 208 
(16% within 5 years) and we suggest that issues of power and the sample size required should be 209 
carefully evaluated before including them in type 1 diabetes prevention trials. 210 
A particular strength of this study is the size of the cohort, screened and followed up every 6-12 211 
months according to a standard protocol (14). One limitation is that, in contrast with studies 212 
following infants from birth, the time at which seroconversion has occurred is unknown when 213 
relatives are found to be positive for an autoantibody in the TrialNet PTP. This may potentially lead 214 
to underestimation of the duration of single autoantibody positivity but, since the focus of this 215 
study is the time to further seroconversion to multiple autoantibodies, the time of initial 216 
seroconversion is less relevant in this context. As in other TrialNet studies, we have included 217 
appearance of ICA in the definition of development of multiple autoantibodies because, although 218 
GADA and I-2A contribute to ICA staining (25,26), there is not complete overlap and previous 219 
analyses in the PTP cohort have demonstrated that ICA are associated with additional risk (20).  220 
Although the determinants of islet autoimmunity underlying type 1 diabetes remain unknown, 221 
accumulating evidence suggests that it develops through multistep involvement of several 222 
pathogenetic pathways (27). Accordingly, interventions at an earlier stage might rely on simpler 223 
approaches, such as antigen based therapies, while at a later stage, a more complex approach, 224 
based for instance on combination therapies, is likely to be necessary to halt or delay the 225 
progression of the disease process (28). Based on our current ability to predict type 1 diabetes, 226 
single autoantibody positivity is the earliest detectable sign of the ongoing autoimmune process, 227 
when the chances of a successful intervention could be greatest. The evidence of heterogeneity in 228 
the progression of islet autoimmunity in relatives of the TrialNet PTP study, the largest study 229 
cohort ever screened and followed up, calls for different therapeutic approaches in single 230 
autoantibody positive individuals with IAA or GADA, with the highest potential for success in 231 
interventions designed for early childhood in IAA-positive and no later than adolescence in GADA-232 
positive individuals. 233 
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Legend to table and figures 334 
 335 
Table 1. Risk of developing multiple autoantibodies within 5 yr in single autoantibody-positive 336 
relatives categorized by age (95% CI). 337 
 338 
Figure 1: GADA-positive (panel A, n=99) and IAA-positive participants (panel B, n=24) who 339 
developed additional autoantibodies within 5 years subdivided by age group. Among the relatives 340 
who progressed, 17/24 (71%) with IAA vs. 27/99 (27%) GADA were aged <8 years (p<0.05). 341 
 342 
Figure 2.- Time from initial detection of: A) single GADA to first detection of multiple antibodies in 343 
relatives aged <14 years (black line) and ≥14 years (grey line); and B) of single IAA to first detection 344 
of multiple antibodies in relatives aged <4 years (black line) and ≥4 years (grey line) 345 
346 
Table 1 - Risk of developing multiple autoantibodies within 5 yr in single autoantibody-positive 347 
relatives categorized by age (95% CI)  348 
 349 
Antibody type Age at entry (n) Overall 
<8 yr 8-11 yr 12-17yr >18 yr 
GADA (n) 107 113 117 372 709 
- Risk  35% (24-46) 38% (24-51) 28% (14-41) 16% (10-22) 25% (20-30) 
IAA (n) 69 33 43 91 236 
- Risk  37% (22-52) 4% (0-11) 13% (0-34) 13% (0-25) 19% (11-27) 
IA-2A (n) 7 11 9 22 49 
- Risk  Insufficient number of subjects to assess 23% (7-38) 
 350 
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